Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis

Circ Res. 2021 May 28;128(11):1616-1625. doi: 10.1161/CIRCRESAHA.120.318556. Epub 2021 Apr 7.

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT03182699.

Keywords: fibroblast growth factor; hypertrophy; renal dialysis.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Death, Sudden, Cardiac / prevention & control
  • Disease Progression
  • Female
  • Fibroblast Growth Factor-23 / blood*
  • Humans
  • Hydroxycholecalciferols / administration & dosage
  • Hydroxycholecalciferols / adverse effects
  • Hydroxycholecalciferols / therapeutic use*
  • Hyperparathyroidism, Secondary / blood
  • Hyperparathyroidism, Secondary / etiology
  • Hypertrophy, Left Ventricular / blood
  • Hypertrophy, Left Ventricular / diagnostic imaging
  • Hypertrophy, Left Ventricular / drug therapy*
  • Hypertrophy, Left Ventricular / etiology
  • Hypocalcemia / chemically induced
  • Intention to Treat Analysis
  • Klotho Proteins / blood
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood
  • Peptides / administration & dosage
  • Peptides / adverse effects
  • Peptides / therapeutic use*
  • Phosphates / blood
  • Renal Dialysis*
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / therapy*
  • Single-Blind Method

Substances

  • FGF23 protein, human
  • Hydroxycholecalciferols
  • Parathyroid Hormone
  • Peptides
  • Phosphates
  • etelcalcetide hydrochloride
  • Fibroblast Growth Factor-23
  • Klotho Proteins
  • alfacalcidol

Associated data

  • ClinicalTrials.gov/NCT03182699